What are the recommended dosing schedules and contraindications for inactivated polio vaccine (IPV) and oral polio vaccine (OPV)?

Polio Vaccine: Dosing Schedules and Contraindications

In the United States, only inactivated poliovirus vaccine (IPV) should be used for routine immunization, administered as a 4-dose series at ages 2 months, 4 months, 6-18 months, and 4-6 years. 1

Current U.S. Vaccination Policy

The U.S. exclusively uses IPV to eliminate the risk of vaccine-associated paralytic poliomyelitis (VAPP), a rare but serious complication associated with oral poliovirus vaccine (OPV). 1 Since 2000, no OPV has been distributed in the United States. 1

IPV Dosing Schedule for Children

Standard Primary Series

• Dose 1: 2 months of age 1
• Dose 2: 4 months of age 1
• Dose 3: 6-18 months of age 1
• Dose 4 (booster): 4-6 years of age 1

Critical Timing Requirements

• Minimum age for first dose: 6 weeks 1
• Minimum interval between doses 1-2 and 2-3: 4 weeks 1
• Minimum interval between doses 3-4: 6 months (not 4 weeks) 1
• Final dose requirement: Must be administered at age ≥4 years regardless of number of previous doses 1

Important Precaution for Infants

Avoid using minimum age and minimum intervals in the first 6 months of life unless the child faces imminent poliovirus exposure (e.g., during an outbreak or travel to polio-endemic regions), as shorter intervals and earlier start dates lead to lower seroconversion rates. 1

IPV Administration Technique

Route and Site

• Infants and young children: Intramuscular or subcutaneous injection in the anterolateral thigh 2
• Older children and adults: Intramuscular or subcutaneous injection in the deltoid area 2

Critical Safety Points

• Never administer intravenously 2
• Do not inject into or near blood vessels and nerves 2
• If blood or suspicious discoloration appears in the syringe, discard and repeat with new dose at different site 2

Combination Vaccines

When using DTaP-IPV/Hib (Pentacel) for 4 doses at ages 2,4,6, and 15-18 months, an additional booster dose of IPV-containing vaccine must be administered at age 4-6 years, resulting in an acceptable 5-dose IPV series. 1 The minimum interval from dose 4 to dose 5 should be at least 6 months. 1

Catch-Up Vaccination for Children

Children with incomplete polio vaccination series should receive sufficient additional doses to complete the series. 2 There is no need to restart the series regardless of time elapsed between doses. 2 Interruption of the schedule does not interfere with final immunity. 2

Adult Vaccination

Unvaccinated Adults at Increased Risk

The 2023 ACIP recommendations expanded adult vaccination guidance: All U.S. adults aged ≥18 years who are known or suspected to be unvaccinated or incompletely vaccinated should complete a primary polio vaccination series with IPV. 3 This change followed the 2022 detection of vaccine-derived poliovirus type 2 transmission in New York. 3

Primary Series Schedule for Adults

Standard schedule (preferred):

• Two 0.5 mL doses given 1-2 months apart 2
• Third 0.5 mL dose given 6-12 months after second dose 2

Accelerated schedules when time is limited:

• If <3 months but >2 months available: Three doses at least 1 month apart 2
• If only 1-2 months available: Two 0.5 mL doses at least 1 month apart 2
• If <1 month available: Single 0.5 mL dose 2

Incompletely Vaccinated Adults

Adults at increased risk who received fewer than three doses of any polio vaccine (OPV, conventional IPV, or combination) should receive at least one 0.5 mL dose of IPV, with additional doses as time permits to complete the primary series. 2

Completely Vaccinated Adults

Adults at increased risk who previously completed a primary series can receive a single 0.5 mL booster dose of IPV. 2

Contraindications

Absolute Contraindications

IPV is contraindicated in persons with:

• History of hypersensitivity to any vaccine component, including: 2
  • 2-phenoxyethanol 2
  • Formaldehyde 2
  • Neomycin 2
  • Streptomycin 2
  • Polymyxin B 2
• Anaphylaxis or anaphylactic shock within 24 hours of a previous dose 2

Precautions

Defer vaccination in persons with acute febrile illness until after recovery. 2 However, minor illnesses such as mild upper respiratory infections with or without low-grade fever are not reasons to postpone vaccination. 2

OPV Considerations (Non-U.S. Context)

While OPV is no longer used in the United States, it remains relevant globally. 1 OPV carries a risk of vaccine-associated paralytic poliomyelitis and can lead to vaccine-derived polioviruses (VDPVs) due to acquired neurovirulence. 4 During January 2023-June 2024,74 cVDPV outbreaks were detected in 39 countries, predominantly in Africa. 5

Key Clinical Pitfalls to Avoid

• Do not use 4-week intervals between doses 3 and 4—the minimum is now 6 months 1
• Do not forget the final dose at age ≥4 years, even if the child has received multiple earlier doses 1
• Do not use accelerated schedules in infants <6 months unless facing imminent poliovirus exposure, as this reduces immunogenicity 1
• Do not mix or reconstitute IPV with other vaccines 2